Annovis Bio, Inc. financial data

Symbol
ANVS on NYSE
Industry
Pharmaceutical Preparations
Location
101 Lindenwood Drive, Suite 225, Malvern, PA
State of incorporation
DE
Fiscal year end
December 31
Former names
QR Pharma, Inc. (to 3/15/2019)
Latest financial report
10-K - Q4 2024 - Mar 21, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 345 % -57.8%
Debt-to-equity 265 % +264%
Return On Equity -873 % -54.5%
Return On Assets -239 % +26.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 19.5M shares +77%
Common Stock, Shares, Outstanding 14.1M shares +34.4%
Entity Public Float 51.3M USD -43.9%
Common Stock, Value, Issued 1.41K USD +34.4%
Weighted Average Number of Shares Outstanding, Basic 12.2M shares +35%
Weighted Average Number of Shares Outstanding, Diluted 12.2M shares +35.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 20M USD -48.5%
General and Administrative Expense 6.7M USD +7.29%
Operating Income (Loss) -26.7M USD +40.7%
Nonoperating Income (Expense) 2.1M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -40.9M USD +1.87%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -24.6M USD +56.2%
Earnings Per Share, Basic -2.02 USD/shares +67.6%
Earnings Per Share, Diluted -2.31 USD/shares +62.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 10.6M USD +83.4%
Assets, Current 7.81M USD -69.4%
Assets 13.9M USD +36.4%
Accounts Payable, Current 2.31M USD +78.4%
Employee-related Liabilities, Current 365K USD +277%
Liabilities, Current 3.88M USD -9.3%
Liabilities 4.62M USD -74.3%
Retained Earnings (Accumulated Deficit) -135M USD -22.3%
Stockholders' Equity Attributable to Parent 9.31M USD
Liabilities and Equity 13.9M USD +36.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.03M USD +39.5%
Net Cash Provided by (Used in) Financing Activities 4.42M USD +59675%
Common Stock, Shares Authorized 70M shares 0%
Common Stock, Shares, Issued 14.1M shares +34.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.62M USD +77.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 10.6M USD +83.4%
Deferred Tax Assets, Valuation Allowance 37.2M USD +23.6%
Deferred Tax Assets, Gross 37.2M USD +23.6%
Deferred Tax Assets, Operating Loss Carryforwards 13.6M USD +41.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 2M shares 0%
Additional Paid in Capital 144M USD +40.6%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 393K USD -37.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%